• HYPK Enables Global N-Terminal Acetylation via NatA Ribosome

  2026-07-22

  Lentzsch et al. reveal that HYPK acts as a ribosome exchange factor for NatA, allowing limited NatA to efficiently acetylate a broad portion of the nascent proteome. This insight clarifies the kinetic regulation of cotranslational protein modification and suggests new avenues for understanding protein biogenesis machinery constraints.

• Troglitazone as a PPARγ Agonist: Advanced Workflows in TAM M

  2026-07-22

  Troglitazone is redefining experimental strategy for researchers targeting the PPAR signaling pathway, especially in tumor-associated macrophage (TAM) modulation and metabolic disease studies. This guide translates bench-to-bedside insights into actionable protocols, troubleshooting, and comparative advantages for applied immunometabolism and oncology workflows.

• APEX2 Proximity Labeling Reveals New Functions for Pef1 in S

  2026-07-21

  This study introduces an optimized APEX2-biotin phenol proximity labeling workflow in Schizosaccharomyces pombe, enabling the identification of dynamic protein environments around the kinase Pef1, a Cdk5 ortholog. The findings uncover novel roles for Pef1 in autophagy regulation and DNA damage response, providing a valuable methodological advance for probing transient protein interactions in yeast.

• NVP-BGJ398 Phosphate: Precision FGFR Inhibition in Translati

  2026-07-21

  NVP-BGJ398 phosphate sets a new standard for selective, pan-FGFR pathway inhibition in both cancer and rare skeletal disease models. This guide details practical workflows, key innovations, and troubleshooting strategies that unlock its full potential for preclinical research.

• MK 0893: Precision Glucagon Receptor Antagonist for Diabetes

  2026-07-20

  MK 0893 delivers nanomolar-level, selective inhibition of the glucagon receptor, enabling robust mechanistic and translational workflows in type 2 diabetes models. Its unique extra-helical binding site and predictable pharmacology facilitate reproducible cAMP assays and in vivo glucose control, supported by structural insights from recent crystallography.

• Oleanolic Acid: Mechanistic Leverage for Dual-Loaded Liposom

  2026-07-20

  Explore how oleanolic acid’s unique mechanisms—particularly inducible nitric oxide synthase (iNOS) induction and cyclooxygenase-2 (COX-2) modulation—are transforming dual-loaded liposome workflows in translational antiviral and immune pathway research. This thought-leadership article synthesizes mechanistic insights, protocol guidance, and strategic perspectives anchored by recent breakthroughs in encapsulation efficiency measurement, guiding researchers toward reproducible and clinically relevant outcomes.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ): New Dimensions in S

  2026-07-19

  Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) is revolutionizing calcium signaling research by enabling precise, pathway-focused hematopoietic stem cell mobilization. This article offers unique insight into recent mechanistic discoveries and practical assay implications.

• β-Elemene Suppresses Adipogenesis via AMPK Activation in 3T3

  2026-07-18

  The recent study demonstrates that β-Elemene inhibits adipogenesis and reverses insulin resistance in 3T3-L1 cells by activating the AMPK pathway. These findings offer mechanistic insight into β-Elemene's metabolic regulatory actions and provide a foundation for further research into its potential applications in obesity and metabolic disease models.

• Concanavalin A Targets Conserved N-Glycans for Broad Coronav

  2026-07-17

  This study reveals that concanavalin A (ConA), a plant lectin, broadly inhibits coronavirus entry by binding to conserved N-linked glycosylation sites on the spike protein, blocking membrane fusion required for infection. The findings highlight evolutionarily conserved glycans as promising antiviral targets and inform future research on glycan-focused intervention strategies.

• Pseudo-UTP in mRNA Engineering: Stability, Immunity, and Pra

  2026-07-17

  Discover how pseudo-modified uridine triphosphate (Pseudo-UTP) empowers next-generation mRNA synthesis with enhanced stability and reduced immunogenicity. This in-depth guide uniquely connects biochemical mechanisms to practical assay design, referencing recent vaccine advances.

• Technical Use of Hoechst 33342/PI Double Staining Kit (K2237

  2026-07-16

  The Hoechst 33342/PI Double Staining Kit enables rapid discrimination of apoptotic, necrotic, and viable cells by leveraging differential nuclear and membrane staining for fluorescence-based analysis. This kit is suitable for research workflows requiring assessment of cell death, but it is not intended for diagnostic or clinical applications.

• LPS Protects Macrophages from Antitumor Drugs via System Xc−

  2026-07-16

  This study uncovers how lipopolysaccharide (LPS) selectively protects macrophages from antitumor drug-induced cytotoxicity by upregulating system Xc− and engaging ABCC1-mediated transport. The findings provide mechanistic insights into immune cell preservation during chemotherapy, with practical implications for designing safer, more selective therapeutic strategies.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-07-15

  Anlotinib hydrochloride stands out as a potent multi-target tyrosine kinase inhibitor, delivering superior inhibition of angiogenesis and tumor progression. This article details optimized workflows, troubleshooting strategies, and comparative advantages—empowering researchers to maximize translational impact in cancer studies.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride in Endothelial Inju

  2026-07-15

  5-(N,N-dimethyl)-Amiloride hydrochloride is redefining the precision of Na+/H+ exchanger inhibition in vascular and cardiac research. With robust selectivity and application flexibility, it streamlines workflows for dissecting intracellular pH regulation and protecting against ischemia-reperfusion injury.

• Mitoxantrone Allosterically Degrades ERα via DBD-LBD Interfa

  2026-07-14

  Wang et al. reveal that mitoxantrone, beyond its DNA topoisomerase II inhibition, targets a novel interface between the DNA-binding and ligand-binding domains of estrogen receptor alpha (ERα), leading to proteasomal degradation. This mechanism overcomes resistance in ER-positive breast cancer models and introduces a new paradigm for nuclear receptor inhibition.

458 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page